 |
|
|
| |
Switching from Stable Lopinavir/Ritonavir (LPV/r)-Based to Raltegravir (RAL)-Based Combination Antiretroviral Therapy (ART) Resulted In a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior Virologic Efficacy at Week 24 (SWITCHMRK)
|
| |
| |
Reported by Jules Levin
CROI 2009, Feb 7-12
Montreal Canada
Joseph Eron*1, Jaime Andrade2, Roberto Zajdenverg3, Cassy Workman4, David A. Cooper5, Benjamin Young6, Xia Xu7,
Bach-Yen Nguyen7, Randi Leavitt7, and Peter Sklar7
1University of North Carolina, Chapel Hill, NC, USA; 2Antinguo Hospital Civil de Guadalajara, Guadalajara, Mexico; 3Hospital Escola Sao Francisco de Assis, Rio de Janeiro, Brazil; 4AIDS Research Initiative, Darlinghurst, Australia; 5University of New South Wales, Sydney, Australia; 6Denver Infectious Disease Consultants, Denver, CO, USA; and 7Merck Research Laboratories, West Point, PA, USA
|
| |
|
|
|
|
|
